Post-Vaccine Syndrome

Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)

Documented in peer-reviewed literature. Rare. Real. Disproportionately affects people with specific genetic predispositions.

What it is

Something changed after the shot. You reported it. You were told it was anxiety, coincidence, or something unrelated. You know your own body and you know that isn't the full answer.

Post-vaccine syndrome is documented in the peer-reviewed literature under the clinical name ASIA syndrome — Autoimmune/Inflammatory Syndrome Induced by Adjuvants. The term was formally proposed in 2011 by immunologist Yehuda Shoenfeld and colleagues, based on observed patterns of immune dysregulation following exposure to adjuvants — the compounds added to vaccines to stimulate a stronger immune response.

ASIA syndrome is not a fringe hypothesis. It is published in rheumatology and immunology journals, cited in NIH-indexed literature, and actively researched. It is also rare. The vast majority of people who receive any vaccine do not develop ASIA syndrome or anything resembling it. That rarity is worth stating plainly — because this page is for the people who did, and who deserve an honest accounting of what the research actually says.

The mechanism is not fully understood, but the working model involves an abnormal or prolonged immune response to adjuvant components — most commonly aluminum salts, which are used in many vaccines to enhance immune activation. In genetically predisposed individuals, this immune activation does not resolve cleanly. The immune system remains dysregulated. Symptoms that follow may involve multiple organ systems and can persist for months or years.

Vaccines are not the only adjuvant exposure that has been associated with ASIA-type presentations. Silicone implants, certain mineral oils used in industrial settings, and other immune-stimulating exposures have been documented in the literature as potential triggers in susceptible individuals. ASIA is a syndrome defined by the immune response pattern — not by any single trigger.

Symptoms

The symptom profile of ASIA syndrome overlaps substantially with other post-inflammatory and post-viral conditions. This overlap is one reason it is frequently missed or misattributed.

Core features identified in the literature:

• Myalgia — muscle pain, often diffuse

• Myositis — muscle inflammation, in some cases with documented elevation of muscle enzymes

• Arthralgia and arthritis — joint pain, with or without inflammation markers

• Chronic fatigue — profound and not responsive to rest

• Cognitive impairment — brain fog, memory difficulty, processing issues

• Pyrexia — low-grade fever or temperature dysregulation

• Dry mouth and dry eyes — sicca symptoms overlapping with Sjogren's presentation

• Neurological symptoms — peripheral neuropathy, tingling, numbness

Additional features reported:

• Sleep disruption

• Skin manifestations

• Gastrointestinal symptoms

• Orthostatic intolerance and autonomic nervous system dysregulation

The symptom onset timing varies. Some presentations begin within days of exposure. Others develop over weeks or months — which is one reason the connection to the triggering exposure is frequently not made by the treating physician, particularly if the patient does not raise it directly.

History — How This Got Named

The clinical pattern that would eventually be called ASIA syndrome was being observed before it had a name. Patients with silicone breast implants were reporting systemic inflammatory symptoms. Gulf War veterans — exposed to multiple vaccines on compressed schedules along with other adjuvant-like substances — were reporting a constellation of symptoms that became known as Gulf War Illness. Macrophagic myofasciitis, a condition characterized by aluminum deposits at injection sites with associated systemic symptoms, was documented in French patients in the late 1990s.

In 2011, Shoenfeld and Agmon-Levin published the formal ASIA criteria in the Journal of Autoimmunity, proposing a unified framework for these overlapping presentations. The criteria required at least two major or one major and two minor criteria, along with exclusion of other diagnoses. The paper drew significant attention — and significant controversy — because naming a syndrome associated with vaccines carries immediate political weight regardless of the quality of the underlying science.

That political weight is worth acknowledging directly. Discussion of adverse vaccine responses exists in a polarized environment where legitimate peer-reviewed research gets either weaponized by people with an anti-vaccine agenda or dismissed by people who treat any acknowledgment of risk as an attack on public health. Neither response serves the patients who are actually living with these symptoms.

The research is what it is. ASIA syndrome is documented, rare, and disproportionately affects people with specific genetic predispositions. Acknowledging that honestly is not an anti-vaccine position. It is an accurate one.

The Genetic Predisposition — Who Is at Risk

This is the piece that matters most for understanding why most people have no significant lasting reaction and a small subset do.

A 2024 paper published in Frontiers in Immunology examined the mechanisms behind hypocortisolemic ASIA — a specific presentation involving low cortisol and dysregulated stress-immune axis responses — and formally named HLA-DRB1 as a genetic predisposition factor for abnormal adjuvant response. The HLA-DQ2 haplotype, which underlies celiac disease and several other autoimmune conditions, has also been implicated in abnormal immune activation patterns following adjuvant exposure.

These haplotypes were selected over thousands of years of human evolutionary history because they produced aggressive immune responses that kept people alive through epidemic infectious disease. The immune system built by HLA-DQ2 and HLA-DRB1 is a weapon shaped by survival pressure across millennia. That same hyperreactivity becomes a liability in the context of modern immune challenges — including adjuvant compounds the immune system was not designed to encounter.

The immune system cannot distinguish between a pathogen it needs to fight and an adjuvant compound designed to mimic one. It activates aggressively. In most people, that activation resolves. In people with certain HLA haplotypes, the activation may not resolve cleanly — the immune system keeps searching for a threat, keeps producing inflammatory signals, and does not get the all-clear.

This is not a character flaw. It is not anxiety. It is a documented genetic architecture meeting a modern immune challenge in a way that produces an abnormal outcome.

I'm not a doctor. I'm not telling you to change your medication. The genetic and mechanistic information above is drawn from peer-reviewed immunology literature. Always work with a qualified physician.

The Honest Uncertainty

This page will not tell you that vaccines caused your illness. It also will not tell you that they didn't.

What it can tell you is that the peer-reviewed literature documents a real syndrome — ASIA — in which adjuvant exposure triggers a lasting autoimmune or inflammatory response in genetically predisposed individuals. It can tell you that HLA-DRB1 and HLA-DQ2 are specifically named as genetic risk factors. It can tell you that the symptom profile is documented, the mechanism has a working biological model, and you are not imagining it.

What cannot be established after the fact — for any individual patient — is causation. Autoimmune and post-inflammatory conditions often emerge during periods of immune stress, and vaccinations are not the only immune stressor that can precede symptom onset. Infections, other medications, environmental exposures, and the compounding effects of multiple stressors over time all exist in the same timeline. A temporal relationship — something happened after the shot — is not the same as a causal relationship. Honest science requires acknowledging both the documented syndrome and the limits of what can be established retroactively.

This uncertainty is genuinely difficult to sit with when you are the patient. You know something changed. You know when it changed. The medical system asking you to prove causation when you are already sick and struggling is an additional burden that is not fair and is worth naming as such. Honest uncertainty is not the same as dismissal. It is the accurate description of where the science currently stands.

What you can do about it

There is no FDA-approved treatment protocol for ASIA syndrome. Management follows the same general framework as other post-inflammatory conditions — reduce the immune burden, treat individual symptoms where possible, protect remaining function.

Find a rheumatologist or immunologist familiar with ASIA. This is the specialist most likely to have encountered the syndrome and be familiar with the literature. Not all will be. Bringing the Shoenfeld 2011 paper and the 2024 Frontiers in Immunology paper to the appointment is a reasonable starting point.

Pacing. If post-exertional malaise is part of the picture — and in ASIA presentations with significant fatigue, it frequently is — pacing is the most evidence-supported management approach. Stay within your energy envelope. See the ME/CFS page for the full discussion.

Reduce adjuvant and immune burden where possible. This is a conversation to have with a knowledgeable physician. What it means in practice varies by individual and is not a decision to make alone.

Treat what is treatable. Sleep disruption, pain, and other individual symptoms can sometimes be managed. This is not treatment of the underlying condition — it is reducing the day-to-day burden while the underlying picture is being evaluated.

Document everything. Symptom onset timeline, dates, exposures, prior medical history, family history of autoimmune conditions. The more precisely you can reconstruct the timeline, the more useful the information is to a physician trying to evaluate the picture.

Asking for the right tests

ASIA syndrome has no single diagnostic test. Evaluation focuses on characterizing the immune response and ruling out other conditions.

Ask for:

• HLA typing — specifically HLA-DQ2 and HLA-DRB1. Knowing your genetic predisposition is relevant information regardless of what conclusions it does or doesn't support.

• Complete thyroid panel: TSH, Free T4, Free T3, TPO antibodies, Thyroglobulin antibodies. Thyroid autoimmunity is frequently associated with ASIA presentations.

• ANA screen and full autoimmune panel — to characterize what autoimmune processes may be active

• Complement levels — C3, C4. Low complement can indicate ongoing immune complex activity.

• CBC with differential and complete metabolic panel

• Ferritin and inflammatory markers — ESR, CRP

• Vitamin D, B12, folate — deficiencies are common in post-inflammatory states and are treatable

• Creatine kinase (CK) — to evaluate for myositis if muscle pain and weakness are prominent

• Tilt table test or NASA lean test — if orthostatic intolerance is present

A normal result is not a clearance. The standard panel is not designed to detect the immune dysregulation that ASIA produces. Push past the first clean results if the clinical picture is strong.

Personal note

In 2019, during the Fremont flood — while six months of displacement and processed food were already compounding everything — I received a tetanus booster as part of flood recovery. Six months later I crashed. Completely and differently than anything before.

I cannot establish causation. I want to be honest about that. There were too many variables in that window — the food, the stress, the physical displacement, the immune burden of the flood environment itself — to point at any single trigger and say that was it. What I can say is that the tetanus booster is part of the documented timeline, and I am not going to scrub it from the record to make the picture cleaner than it actually is.

What I know is that I carry HLA-DQ2. I know that HLA-DQ2 and HLA-DRB1 are specifically named in the peer-reviewed literature as genetic predispositions for abnormal adjuvant response. I know that my immune system does not do things quietly or proportionately — it never has. Whether the booster was a trigger, a contributing factor, or a coincidence in a timeline that was already headed toward a crash — I genuinely do not know. Honest uncertainty is the most accurate thing I can offer.

What I do know is that if you are sitting with a similar timeline — something changed, you know when, nobody will look at the full picture — you are not alone. The research exists. The syndrome has a name. You are not imagining it.

And if you have been in that waiting room hoping the next specialist will find something that at least comes with a treatment protocol — that thought is more common than anyone says out loud. You are not broken for having it.

Sources

• Shoenfeld Y., Agmon-Levin N. (2011) — ASIA — Autoimmune/inflammatory syndrome induced by adjuvants. Journal of Autoimmunity. — PubMed PMID: 20708902

• Frontiers in Immunology (2024) — Hypocortisolemic ASIA: a vaccine- and chronic infection-induced syndrome behind the origin of long COVID and myalgic encephalomyelitis — PubMed PMID: 39044822

• Frontiers in Immunology (2025) — The origin of autoimmune diseases: is there a role for ancestral HLA-II haplotypes in immune hyperactivity

• Agmon-Levin N. et al. (2014) — Vaccines and autoimmunity. Nature Reviews Rheumatology. — PubMed PMID: 24323044

• Gherardi R.K. et al. (2019) — Macrophagic myofasciitis: characterization and pathophysiology. Lupus. — PubMed PMID: 30898030

• Harley et al. (2018) — Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nature Genetics. — PubMed

• CDC — Vaccine Safety: cdc.gov/vaccinesafety

• 2015 Institute of Medicine Report — Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness — NAP.edu